On the stock market since 2015, it operates in the world of health and science. It has 84 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 9% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
Sales run at $89.3M a year. A small number, but proof the product has real buyers.
A loss of $37.8M against $89.3M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.08. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
On our five-subject report card, MNNGF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MNNGF is a high-risk stock — not yet profitable, and its future rides on its product catching on.